A5025590744- Medical Imaging and Pathology Studies
- Heterotopic Ossification and Related Conditions
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Parathyroid Disorders and Treatments
- Lipoproteins and Cardiovascular Health
- Long-Term Effects of COVID-19
- Cardiac, Anesthesia and Surgical Outcomes
- COVID-19 and healthcare impacts
- Head and Neck Cancer Studies
- Cancer, Lipids, and Metabolism
- Oral health in cancer treatment
- Cardiac tumors and thrombi
- Delphi Technique in Research
- Acute Myocardial Infarction Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Nutrition and Health in Aging
- Enhanced Recovery After Surgery
- Energy Load and Power Forecasting
- Erythropoietin and Anemia Treatment
- Bone Tumor Diagnosis and Treatments
- Cleft Lip and Palate Research
- Ultrasound in Clinical Applications
- Alcohol Consumption and Health Effects
- Medical Imaging Techniques and Applications
Regeneron (United States)
2020-2024
Mental Health Association of Westchester County
2024
Hôpital Cochin
2024
Assistance Publique – Hôpitaux de Paris
2024
Sorbonne Paris Cité
2024
Université Paris Cité
2024
Institut national de recherche en informatique et en automatique
2024
The University of Texas Health Science Center at Houston
2022
Institut de Virologie
2021
University of Minnesota
2017
An urgent global quest for effective therapies to prevent and treat coronavirus disease 2019 (COVID-19) is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987 REGN10933) that targets nonoverlapping epitopes on the severe acute respiratory syndrome 2 (SARS-CoV-2) spike protein. In this report, we evaluate in vivo efficacy antibody both rhesus macaques, which may model mild disease, golden hamsters, more disease. demonstrate REGN-COV-2 can...
To examine oral complications 6 months after modern radiation therapy (RT) for head and neck cancer (HNC).Prospective multicenter cohort study of patients with HNC receiving intensity-modulated or more advanced RT. Stimulated whole salivary flow, maximal mouth opening, mucositis, pain, health-related quality life (OH-QOL), hygiene practices were measured in 372 subjects pre-RT 216 at from the start RT.Mean stimulated flow declined 1.09 to 0.47 ml/min (p < .0001). Mean opening reduced 45.58...
Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (n = 20) or placebo 24) period 1 (28 weeks), followed open-label weeks; n 43). The primary end points safety for 1, activity size of HO lesions. All experienced at least one treatment-emergent adverse event during notably...
Abstract Background: Racial/ethnic minorities are more likely than non-Hispanic whites (NHW) to be diagnosed with advanced stage hepatocellular carcinoma (HCC). We examined the role of neighborhood disadvantage as a mediator association between race/ethnicity and HCC at diagnosis. Methods: used data from cases in Texas 2007 2015. were classified local versus regional/advanced stage. A mediation model approach was estimate average direct effect, mediated (indirect) total proportion by Area...
ABSTRACT Background Fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder caused by mutations in the gene encoding activin A receptor type 1 ( ACVR1) , is characterized painful flare-ups and cumulative heterotopic ossification (HO). Garetosmab, a fully-human monoclonal antibody blocking A, prevents HO FOP mice. Methods LUMINA-1 NCT03188666 ) was phase 2, multi-center, randomized, double-blind, placebo-controlled study evaluating safety, tolerability, effects on of intravenous...
Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) persons at high risk disease 2019 (COVID-19; n = 3816), evolution individual was assessed for resolution patterns across factors, baseline SARS-CoV-2-specific antibody responses against S1 N domains. CAS IMD versus placebo provided statistically significant 17/23 symptoms, greater...
Abstract Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disorder, characterized by progressive heterotopic ossification (HO) and painful soft-tissue inflammatory flare-ups. This was a post hoc analysis from phase 2 (NCT03188666) trial in which adults with FOP received intravenous anti-activin A antibody garetosmab 10 mg/kg or placebo every 4 wk over 28 (Period 1), followed 28-wk open-label treatment extension (Periods 3). Here we describe flare-ups, their relationship to new HO...
Assess the risk of new and worsening cancer events among participants who received lipid-lowering therapy alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor.Pooled post hoc analysis.Six phase 3 or 4 placebo-controlled randomised trials with alirocumab.A total 24,070 patients from safety population complete dosing data (alirocumab, n = 12,533; placebo, 11,537).Alirocumab 75 mg, alirocumab 150 mg increasing to if low-density lipoprotein cholesterol <50 mg/dL not achieved,...
Introduction: Preclinical data suggest myostatin and activin A are important negative regulators of muscle mass. Trevogrumab (a monoclonal antibody [mAb]) binds blocks signalling, while garetosmab mAb) A, AB AC signalling. Here, the effects administering trevogrumab garetosmab, alone or in combination, on body composition healthy participants was assessed. Methods: This Phase 1, double-blind, placebo-controlled study randomized males postmenopausal females to single-dose multiple-dose parts...
Increased use of antiviral monoclonal antibodies (mAbs) for treatment and prophylaxis necessitates better understanding their impact on endogenous immunity to vaccines viruses. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presented an opportunity study in individuals who received mAbs were subsequently immunized with encoding the mAb-targeted viral spike antigen. Here, we describe administration antibody combination, casirivimab plus imdevimab (CAS+IMD), immune...
What is this summary about? This a plain language of clinical research study called LUMINA-1. investigated medicine garetosmab in adults with fibrodysplasia ossificans progressiva, or FOP. FOP very rare disease that causes new bone to form places where it does not usually develop (also known as heterotopic ossification). In FOP, when formed areas supposed to, results mature bone. The build-up makes difficult for people move, which means they often require the use wheelchair other mobility...
Plasma lipid levels are modulated by systemic infection and inflammation; it is unknown whether these changes reflect inflammatory responses or caused directly pathogen presence. We explored the hypothesis that anti-inflammatory intervention via interleukin 6 receptor (IL-6R) blockade would influence plasma during severe evaluated association of with clinical outcomes. Sarilumab (monoclonal antibody blocking IL-6R) efficacy was previously assessed in patients coronavirus disease 2019...
Abstract Disclosure: D. Gonzalez Trotter: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Srinivasan: K. Mohammadi: A.N. Economides: G. Herman: S. Mellis: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disorder characterized by the deposition of bone in soft tissues, known as heterotopic ossification (HO). The formation HO lesions sporadic and sometimes associated with painful swellings (flares), which subside over time. LUMINA-1, a phase 2, randomized, double-blind...
Background: Patients with acute coronary syndrome (ACS) and elevated LDL-C levels despite statin therapy may have genetic dyslipidemias, such as heterozygous familial hypercholesterolemia (HeFH) or type III hyperlipoproteinemia (T3HLP), which convey heightened cardiovascular (CV) risk due to lifelong exposure. In this post hoc analysis of the ODYSSEY OUTCOMES trial, we identified patients likely affected by HeFH T3HLP evaluated lipid-lowering CV efficacy alirocumab. Methods: Clinical was...
It is commonly reported that rare variants may be more functionally related to complex diseases than common variants. However, individual variant association tests remain challenging due low minor allele frequency in the available samples. This paper proposes an expectation maximization variable selection (EMVS) method simultaneously detect and at level using family trio data. TRIO_RVEMVS was assessed both large (1500 families) small (350 datasets based on simulation. The performance of...
Abstract Disclosure: D. Gonzalez Trotter: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; J. McGinniss: A.N. Economides: K. Mohammadi: A.J. Rankin: B. Musser: S. Mellis: E. Forleo-Neto: G. Herman: Background: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disorder caused by mutations in the activin-A receptor type 1 (ACVR1) gene that render it responsive to activin-A, a ligand normally antagonizes signaling from ACVR1. FOP characterized deposition of bone soft tissues...
Abstract Disclosure: K.M. Dahir: Consulting Fee; Self; Alexion Pharmaceuticals, Inc., Ultragenyx, Inozyme, AM Pharma. Grant Recipient; Regeneron AstraZeneca, Ultragenyx. J. McGinniss: Employee; Pharmaceuticals. Stock Owner; E. Forleo-Neto: S. Mellis: R.J. Sanchez: M. Di Rocco: Research Investigator; Ipsen. R. Keen: Advisory Board Member; International Clinical Council on FOP and IFOPA Registry. Ipsen, Clementia. P. Orcel: C. Roux: Amgen Inc. Kyowa, Kirin Brewery, Tabarkiewicz: Speaker;...